India’s first indigenous CAR-T cell therapy, NexCAR19, developed by ImmunoACT, an IIT Bombay spin-off, marks a major leap in affordable cancer care. Supported by DBT and BIRAC, the therapy reprograms a patient’s immune cells to fight blood cancers like Acute Lymphocytic Leukemia (ALL). Clinical trials at Tata Memorial Centre have shown promising results, positioning India as a rising hub for cell and gene therapy innovation.
Related Posts
PIL in SC seeking judicial intervention to address rising air pollution levels
Post Views: 5 The plea said the current air pollution…
Trump’s Pharma Tariff Plan Could Spark Cost and Supply Shock
Post Views: 30 President Trump has proposed imposing tariffs of…
83% Indians carry antibiotic-resistant bacteria, finds study
Post Views: 10 During the study, doctors examined 1,200 patients…